BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuner R. Lung Cancer Gene Signatures and Clinical Perspectives. Microarrays (Basel) 2013;2:318-39. [PMID: 27605195 DOI: 10.3390/microarrays2040318] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Rolff J, Becker M, Merk J, Hoffmann J, Fichtner I. Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts. Targ Oncol 2016;11:507-14. [DOI: 10.1007/s11523-015-0415-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
2 Li W, Freudenberg J, Oswald M. Principles for the organization of gene-sets. Comput Biol Chem 2015;59 Pt B:139-49. [PMID: 26188561 DOI: 10.1016/j.compbiolchem.2015.04.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
3 Leong D, Rai R, Nguyen B, Lee A, Yip D. Advances in adjuvant systemic therapy for non-small-cell lung cancer. World J Clin Oncol 2014; 5(4): 633-645 [PMID: 25302167 DOI: 10.5306/wjco.v5.i4.633] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
4 Zhang D, Rennhack J, Andrechek ER, Rockwell CE, Liby KT. Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice. Antioxid Redox Signal 2018;29:1535-52. [PMID: 29634345 DOI: 10.1089/ars.2017.7201] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
5 Ma J, Hobbs BP, Stingo FC. Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 2018;27:2093-113. [PMID: 27807177 DOI: 10.1177/0962280216675373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Ma J, Stingo FC, Hobbs BP. Bayesian personalized treatment selection strategies that integrate predictive with prognostic determinants. Biom J 2019;61:902-17. [PMID: 30786040 DOI: 10.1002/bimj.201700323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN Jr, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol 2018;31:947-55. [PMID: 29410488 DOI: 10.1038/s41379-018-0029-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
8 Dalby A, Bailey I. The Robustness of Pathway Analysis in Identifying Potential Drug Targets in Non-Small Cell Lung Carcinoma. Microarrays (Basel) 2014;3:212-25. [PMID: 27600345 DOI: 10.3390/microarrays3040212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]